APGOT-EN7: A Phase 3 Randomized, Open-Label Study of Rinatabart Sesutecan (Rina-S) Plus Pembrolizumab versus Chemotherapy Plus Pembrolizumab for 1L Treatment of Patients with Primary Advanced or Recurrent pMMR Endometrial Cancer.